CNS Pharmaceuticals CEO receives 9,761 stock options, 2035 expiry

Rhea-AI Filing Summary

CNS Pharmaceuticals, Inc. (CNSP) reported a stock option grant to its chief executive officer and director on a Form 4. The filing shows an option to purchase 9,761 shares of common stock at an exercise price of $30 per share, dated 11/17/2025 and expiring on 11/17/2035.

The option was originally approved on 03/11/2025, subject to shareholder approval of the stock option plan, which was obtained on 11/17/2025. The grant vests over 18 months: 50% on the six‑month anniversary of the grant date, 25% on the 12‑month anniversary, and 25% on the 18‑month anniversary, conditioned on continued employment. The reporting person beneficially owns 9,761 derivative securities directly after this transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Climaco John M

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock	9,761	$0.00	--

Holdings After Transaction: Option to purchase common stock — 9,761 shares (Direct)

Footnotes (1)

1. The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025. The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date. Issued in connection with the reporting person's employment with the Company.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Climaco John M

(Last) (First) (Middle)

C/O CNS PHARMACEUTICALS, INC.

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON TX 77027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$30	11/17/2025(1)		A		9,761		(2)	11/17/2035	Common Stock	9,761	$0(3)	9,761	D

Explanation of Responses:

1. The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

2. The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

3. Issued in connection with the reporting person's employment with the Company.

	/s/ Christopher Downs, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CNS Pharmaceuticals (CNSP) report in this Form 4 filing?

The filing reports a stock option grant to the chief executive officer and director of CNS Pharmaceuticals, Inc. for 9,761 options to purchase common stock.

How many stock options were granted to the CNSP executive and at what exercise price?

The executive received an option to purchase 9,761 shares of CNS Pharmaceuticals common stock at an exercise price of $30 per share.

When do the CNSP stock options vest for the reporting person?

The options vest as follows: 50% on the six‑month anniversary of the 03/11/2025 grant date, 25% on the 12‑month anniversary, and 25% on the 18‑month anniversary, subject to continued employment.

What approvals were required for the CNSP stock option grant?

The option grant was approved by the compensation committee on 03/11/2025, subject to shareholder approval of the stock option plan, which shareholders granted on 11/17/2025.

What is the expiration date of the CNS Pharmaceuticals (CNSP) stock options?

The stock options reported in the Form 4 expire on 11/17/2035.

How many derivative securities does the CNSP reporting person own after this transaction?

Following the reported transaction, the reporting person beneficially owns 9,761 derivative securities directly.

What role does the reporting person hold at CNS Pharmaceuticals (CNSP)?

The reporting person is a director and serves as the Chief Executive Officer of CNS Pharmaceuticals, Inc.